{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:00:11Z","timestamp":1772164811736,"version":"3.50.1"},"reference-count":53,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>We developed a novel FTY720 prodrug (pro-FTY) that specifically inhibits sphingosine-1-phosphate signaling in cancer cells using a novel drug delivery system that reacts with acrolein. Our objective was to evaluate the efficacy and safety of pro-FTY in preclinical experiments. Ten breast cancer cell lines, two multidrug-resistant cell lines, and one normal mammary cell line were used to compare the IC50 values of pro-FTY with those of other drugs. Patient-derived organoids (PDO) were established and utilized for IC50 value comparisons. Drug efficacy was tested in mice bearing either syngeneic 4T1 cell tumors or patient-derived xenograft tumors, and blood analysis (including mass spectrometry) was performed. FTY720 and pro-FTY inhibited the survival of all breast cancer cell lines, including multidrug-resistant cells resistant to paclitaxel or doxorubicin. Unlike pro-FTY, FTY720 inhibited the survival of normal breast cell lines, suggesting that pro-FTY does not affect normal breast cells. Pro-FTY showed reproducible activity against multidrug-resistant PDOs, whereas paclitaxel and doxorubicin did not. Mass spectrometric analysis of pro-FTY\u2013treated mice showed that FTY720 accumulated in tumors but was barely detectable in blood. Importantly, lymphocytopenia occurred in FTY720-treated mice but not in pro-FTY\u2013treated mice. Furthermore, intravenous pro-FTY treatment significantly suppressed tumor growth in mice bearing patient-derived xenograft tumors generated from multidrug-resistant PDOs. In conclusion, pro-FTY inhibited breast cancer, including multidrug-resistant breast cancer, while avoiding lymphocytopenia, highlighting its clinical potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Pro-FTY selectively inhibits sphingosine-1-phosphate signaling in cancer cells using a novel acrolein-responsive drug delivery system that reacts with acrolein. Pro-FTY does not inhibit normal cell growth, thus avoiding lymphocytopenia. Pro-FTY is effective against multidrug-resistant breast cancer with a unique mechanism of action, highlighting its translational and therapeutic potential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0023","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:33:58Z","timestamp":1750217638000},"page":"981-993","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3462-253X","authenticated-orcid":false,"given":"Masayuki","family":"Nagahashi","sequence":"first","affiliation":[{"name":"1Division of Breast and Endocrine Surgery, Department of Surgery, Hyogo Medical University, Nishinomiya, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7570-9255","authenticated-orcid":false,"given":"Miki","family":"Komatsu","sequence":"additional","affiliation":[{"name":"1Division of Breast and Endocrine Surgery, Department of Surgery, Hyogo Medical University, Nishinomiya, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4501-3903","authenticated-orcid":false,"given":"Sayaka","family":"Urano","sequence":"additional","affiliation":[{"name":"1Division of Breast and Endocrine Surgery, Department of Surgery, Hyogo Medical University, Nishinomiya, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9049-6808","authenticated-orcid":false,"given":"Mamiko","family":"Kuroiwa","sequence":"additional","affiliation":[{"name":"1Division of Breast and Endocrine Surgery, Department of Surgery, Hyogo Medical University, Nishinomiya, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5783-3926","authenticated-orcid":false,"given":"Yuria","family":"Takahashi","sequence":"additional","affiliation":[{"name":"2Department of Chemical Science and Engineering, School of Materials and Chemical Technology, Institute of Science Tokyo, Ookayama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6650-5040","authenticated-orcid":false,"given":"Koji","family":"Morimoto","sequence":"additional","affiliation":[{"name":"3Biofunctional Synthetic Chemistry Laboratory, RIKEN Pioneering Research Institute, Wako, Japan."},{"name":"4Department of Human Health Science, Faculty of Human Sciences, Osaka International University, Moriguchi, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9056-447X","authenticated-orcid":false,"given":"Ambara R.","family":"Pradipta","sequence":"additional","affiliation":[{"name":"2Department of Chemical Science and Engineering, School of Materials and Chemical Technology, Institute of Science Tokyo, Ookayama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6932-4802","authenticated-orcid":false,"given":"Katsunori","family":"Tanaka","sequence":"additional","affiliation":[{"name":"2Department of Chemical Science and Engineering, School of Materials and Chemical Technology, Institute of Science Tokyo, Ookayama, Japan."},{"name":"3Biofunctional Synthetic Chemistry Laboratory, RIKEN Pioneering Research Institute, Wako, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8535-4008","authenticated-orcid":false,"given":"Yasuo","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"1Division of Breast and Endocrine Surgery, Department of Surgery, Hyogo Medical University, Nishinomiya, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"2025061803335052000_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025061803335052000_bib2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(16)31392-7","article-title":"The global burden of women\u2019s cancers: a grand challenge in global health","volume":"389","author":"Ginsburg","year":"2017","journal-title":"Lancet"},{"key":"2025061803335052000_bib3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3322\/caac.21863","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025061803335052000_bib4","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1530\/ERC-21-0293","article-title":"Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer","volume":"29","author":"Alataki","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"2025061803335052000_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clbc.2016.05.012","article-title":"Classification, treatment strategy, and associated drug resistance in breast cancer","volume":"16","author":"Tang","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"2025061803335052000_bib6","doi-asserted-by":"crossref","first-page":"1012552","DOI":"10.3389\/fphar.2022.1012552","article-title":"Drug-resistant HER2-positive breast cancer: molecular mechanisms and overcoming strategies","volume":"13","author":"Wu","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025061803335052000_bib7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future","volume":"395","author":"Spring","year":"2020","journal-title":"Lancet"},{"key":"2025061803335052000_bib8","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/cancers16122259","article-title":"Resistance to targeted inhibitors of the PI3K\/AKT\/mTOR pathway in advanced oestrogen-receptor-positive breast cancer","volume":"16","author":"Browne","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025061803335052000_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.18632\/oncoscience.610","article-title":"Molecular mechanism of PARP inhibitor resistance","volume":"11","author":"Huang","year":"2024","journal-title":"Oncoscience"},{"key":"2025061803335052000_bib10","first-page":"22","article-title":"Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer","volume":"7","author":"Saleh","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"2025061803335052000_bib11","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1111\/cas.15497","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"113","author":"Nagasaki","year":"2022","journal-title":"Cancer Sci"},{"key":"2025061803335052000_bib12","doi-asserted-by":"crossref","first-page":"25851","DOI":"10.1074\/jbc.R200007200","article-title":"Sphingosine 1-phosphate, a key cell signaling molecule","volume":"277","author":"Spiegel","year":"2002","journal-title":"J Biol Chem"},{"key":"2025061803335052000_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/pr.107.07113","article-title":"\u201cInside-out\u201d signaling of sphingosine-1-phosphate: therapeutic targets","volume":"60","author":"Takabe","year":"2008","journal-title":"Pharmacol Rev"},{"key":"2025061803335052000_bib14","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1111\/cas.13802","article-title":"The role of sphingosine-1-phosphate in inflammation and cancer progression","volume":"109","author":"Nagahashi","year":"2018","journal-title":"Cancer Sci"},{"key":"2025061803335052000_bib15","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/0008-5472.CAN-11-2167","article-title":"Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis","volume":"72","author":"Nagahashi","year":"2012","journal-title":"Cancer Res"},{"key":"2025061803335052000_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-7091-1511-4_1","article-title":"Sphingosine kinase\/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance","volume":"216","author":"Selvam","year":"2013","journal-title":"Handb Exp Pharmacol"},{"key":"2025061803335052000_bib17","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/1535-7163.MCT-05-0021","article-title":"Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma","volume":"4","author":"Ho","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"2025061803335052000_bib18","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1038\/oncsis.2015.16","article-title":"The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ER\u03b1 expression and enhances hormonal therapy for breast cancer","volume":"4","author":"Hait","year":"2015","journal-title":"Oncogenesis"},{"key":"2025061803335052000_bib19","doi-asserted-by":"crossref","first-page":"100670","DOI":"10.1016\/j.jbior.2019.100670","article-title":"Sphingosine-1-phosphate signaling: a novel target for simultaneous adjuvant treatment of triple negative breast cancer and chemotherapy-induced neuropathic pain","volume":"75","author":"Singh","year":"2020","journal-title":"Adv Biol Regul"},{"key":"2025061803335052000_bib20","first-page":"1039","article-title":"Sphingosine-1-phosphate analogue FTY720 exhibits a potent anti-proliferative effect on glioblastoma cells","volume":"57","author":"Kolodziej","year":"2020","journal-title":"Int J Oncol"},{"key":"2025061803335052000_bib21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1146\/annurev-immunol-081519-083952","article-title":"Finding a way out: S1P signaling and immune cell migration","volume":"38","author":"Baeyens","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"2025061803335052000_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.13219","article-title":"Get me out of here: sphingosine 1-phosphate signaling and T cell exit from tissues during an immune response","volume":"317","author":"Hallisey","year":"2023","journal-title":"Immunol Rev"},{"key":"2025061803335052000_bib23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-017-4380-8","article-title":"New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth","volume":"165","author":"Alshaker","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"2025061803335052000_bib24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025061803335052000_bib25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"2025061803335052000_bib26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"2025061803335052000_bib27","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"2025061803335052000_bib28","doi-asserted-by":"crossref","first-page":"9798","DOI":"10.1039\/D1CC03590H","article-title":"Biofunctional chemistry and reactivity of biogenic acrolein for cancer diagnosis and therapy","volume":"57","author":"Pradipta","year":"2021","journal-title":"Chem Commun (Camb)"},{"key":"2025061803335052000_bib29","doi-asserted-by":"crossref","first-page":"13367","DOI":"10.3390\/ijms222413367","article-title":"Plasma sphingosine-1-phosphate levels are associated with progression of estrogen receptor-positive breast cancer","volume":"22","author":"Ikarashi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025061803335052000_bib30","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.21873\/anticanres.13559","article-title":"The effects of eribulin on breast cancer microenvironment identified using eribulin-resistant breast cancer cell lines","volume":"39","author":"Goto","year":"2019","journal-title":"Anticancer Res"},{"key":"2025061803335052000_bib31","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s41596-020-00474-1","article-title":"Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids","volume":"16","author":"Dekkers","year":"2021","journal-title":"Nat Protoc"},{"key":"2025061803335052000_bib32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"2025061803335052000_bib33","doi-asserted-by":"crossref","first-page":"1801479","DOI":"10.1002\/advs.201801479","article-title":"Cascade reaction in human live tissue allows clinically applicable diagnosis of breast cancer morphology","volume":"6","author":"Tanei","year":"2019","journal-title":"Adv Sci (Weinh)"},{"key":"2025061803335052000_bib34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10549-014-3118-0","article-title":"An improved syngeneic orthotopic murine model of human breast cancer progression","volume":"147","author":"Rashid","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2025061803335052000_bib35","doi-asserted-by":"crossref","first-page":"8458","DOI":"10.1158\/1078-0432.CCR-05-0447","article-title":"FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2025061803335052000_bib36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jss.2018.05.085","article-title":"Upregulation of phosphorylated sphingosine kinase 1 expression in colitis-associated cancer","volume":"231","author":"Yuza","year":"2018","journal-title":"J Surg Res"},{"key":"2025061803335052000_bib37","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-023-07086-9","article-title":"Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin","volume":"202","author":"Bun","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"2025061803335052000_bib38","doi-asserted-by":"crossref","first-page":"100094","DOI":"10.1016\/j.tchem.2024.100094","article-title":"Highly efficient and selective anticancer approach through acrolein-triggered cycloaddition chemistry in patient-derived xenografts: mechanistic and preclinical investigation","volume":"12","author":"Takahashi","year":"2024","journal-title":"Tetrahedron Chem"},{"key":"2025061803335052000_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid metabolism in cancer signalling and therapy","volume":"18","author":"Ogretmen","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"2025061803335052000_bib40","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.3390\/ijms25063354","article-title":"Targeting sphingosine-1-phosphate signaling in breast cancer","volume":"25","author":"Nagahashi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025061803335052000_bib41","doi-asserted-by":"crossref","first-page":"108631","DOI":"10.1016\/j.pharmthera.2024.108631","article-title":"Orthotopic and metastatic tumour models in preclinical cancer research","volume":"257","author":"Stribbling","year":"2024","journal-title":"Pharmacol Ther"},{"key":"2025061803335052000_bib42","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.ejso.2022.04.003","article-title":"Comparison of \u201cclick-to-sense\u201d assay with frozen section analysis using simulated surgical margins in breast cancer patients","volume":"48","author":"Kubo","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"2025061803335052000_bib43","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1039\/D0SC06083F","article-title":"Targeted 1,3-dipolar cycloaddition with acrolein for cancer prodrug activation","volume":"12","author":"Pradipta","year":"2021","journal-title":"Chem Sci"},{"key":"2025061803335052000_bib44","doi-asserted-by":"crossref","first-page":"9566","DOI":"10.1039\/D4SC00969J","article-title":"Anticancer approach by targeted activation of a global inhibitor of sialyltransferases with acrolein","volume":"15","author":"Kasahara","year":"2024","journal-title":"Chem Sci"},{"key":"2025061803335052000_bib45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ccr.2012.11.013","article-title":"Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer","volume":"23","author":"Liang","year":"2013","journal-title":"Cancer Cell"},{"key":"2025061803335052000_bib46","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1158\/0008-5472.CAN-17-1423","article-title":"Targeting the SphK1\/S1P\/S1PR1 axis that links obesity, chronic inflammation, and breast cancer metastasis","volume":"78","author":"Nagahashi","year":"2018","journal-title":"Cancer Res"},{"key":"2025061803335052000_bib47","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1541-7786.MCR-17-0353","article-title":"ABCC1-exported sphingosine-1-phosphate, produced by sphingosine kinase 1, shortens survival of mice and patients with breast cancer","volume":"16","author":"Yamada","year":"2018","journal-title":"Mol Cancer Res"},{"key":"2025061803335052000_bib48","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1158\/1078-0432.CCR-15-2618","article-title":"The sphingosine-1-phosphate modulator FTY720 targets multiple myeloma via the CXCR4\/CXCL12 pathway","volume":"23","author":"Beider","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025061803335052000_bib49","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.18632\/oncotarget.6564","article-title":"Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"2025061803335052000_bib50","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1038\/s41598-017-06047-9","article-title":"FTY720 induces autophagy-associated apoptosis in human oral squamous carcinoma cells, in part, through a reactive oxygen species\/Mcl-1-dependent mechanism","volume":"7","author":"Bai","year":"2017","journal-title":"Sci Rep"},{"key":"2025061803335052000_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/jop.13498","article-title":"FTY720 increases paclitaxel efficacy in cisplatin-resistant oral squamous cell carcinoma","volume":"53","author":"Torres","year":"2024","journal-title":"J Oral Pathol Med"},{"key":"2025061803335052000_bib52","doi-asserted-by":"crossref","first-page":"120699","DOI":"10.1016\/j.lfs.2022.120699","article-title":"The inhibition of autophagy by spautin boosts the anticancer activity of fingolimod in multidrug-resistant hepatocellular carcinoma","volume":"304","author":"Alhamad","year":"2022","journal-title":"Life Sci"},{"key":"2025061803335052000_bib53","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1159\/000491908","article-title":"Metformin and FTY720 synergistically induce apoptosis in multiple myeloma cells","volume":"48","author":"Zhao","year":"2018","journal-title":"Cell Physiol Biochem"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/6\/981\/3621903\/crc-25-0023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/6\/981\/3621903\/crc-25-0023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:34:07Z","timestamp":1750217647000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/6\/981\/762997\/An-Acrolein-Based-Drug-Delivery-System-Enables"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0023","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29348662","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29348668","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29348656","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29348659","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29348653","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29348665","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7881709","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}